Skip to main content
Fig. 7 | Genome Medicine

Fig. 7

From: Integrative omics analyses broaden treatment targets in human cancer

Fig. 7

Cell line-based validation. a Violin plots show the distribution of drug response (y-axis) of cell lines with drug-associated mutations compared to the background distribution (dark yellow). The type of distribution is indicated in the top gray bar of the panel with distributions of the background, cell lines with mutations in DEPO (Mutational Evidence), and cell lines with putative functional mutations as predicted by HotSpot3D (HotSpot3D). Sensitive and resistant mutations in DEPO are indicated by a green and pink fill color, respectively. Violin plots outlined in a bold black color indicate the cancer-type-specific distribution. The bottom gray bar indicates sample size and P value (Mann-Whitney U test) for the distribution when compared to the background. b The distribution of drug response (y-axis) for three BRAF inhibitors (PLX4720 (1), PLX4720 (2), and dabrafenib) are shown. For each drug, the background distribution and drug response for cell lines with the BRAF V600E mutation in the cancer-type-specific setting and non-specific setting are shown. c Expression outlier scores for genes (y-axis) with significant negative correlation with a paired drug (x-axis) are shown. The intensity of shading corresponds to the number of probes that registered as significant for a gene-drug pair. d Scatter plots of the drug response (y-axis) of Nutlin-3a and expression outlier scores (x-axis) are shown for three different probes of MDM2. The best fit line and P values for the linear regression are also shown. e Scatter plots of the drug response (y-axis) to three different drugs (erlotinib, lapatinib, and afatinib) and expression outlier scores (x-axis) are shown for 1 probe of EGFR. The best fit line and P values for the linear regression are also shown

Back to article page